Print

Cangrelor trial success quickens pulses of Medicines Company investors

Date January 09, 2013

All the Medicines Company needed to do to prove that its blood-thinner cangrelor could outperform Plavix in preventing cardiovascular events and death in patients undergoing heart procedures was change its dosing protocols and the definition of a heart attack. After two trials of the drug were terminated in 2009 when they showed no signs of efficacy, success in the Champion Phoenix test suggests the study was well named.

The news drove shares up 12% to a six-year high of $28.83 yesterday as investors saw the potential to add sales growth to that of its biggest seller, Angiomax, which might face competition in 2019. The big question will be regulators’ views of the changes to the trial design, to which the FDA had not agreed in advance.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2014 EP Vantage Ltd